Novel Treatment Mechanism for Heart Failure Patients
A discussion on the GALACTIC-HF trial presenting a novel approach to treating heart failure, with a focus on reducing heart failure events among a diverse patient population. The trial explores the benefits of Omecamtiv Mecarbil in the treatment algorithm for heart failure alongside established therapies and new options like sodium glucose cotransporter-2 inhibitors and vericiguat.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
EMBARGOED until 10:35am CT 11-13-20 GALACTIC-HF Discussion Paul Heidenreich, MD, MS Stanford University School of Medicine Nov. 12, 2020 #AHA20
Disclosures No Industry Relationships 2
GALACTIC-HF Discussion A novel mechanism for treating heart failure Broad range of symptomatic heart failure patients with reduced left ventricular ejection fraction included More Asian than Black patients enrolled Primary benefit: reduced heart failure events Hospitalization, emergency department visits, urgent care Dimensions of Treatment Benefit Survival Health Status Cost 3
How Might Omecamtiv Mecarbil Fit Into Our Heart Failure Treatment Algorithm? Established Heart Failure Therapies (2017 ACC/AHA Heart Failure Guideline) All with survival benefit 1. Angiotensin receptor blocker/ neprilysin inhibitor, angiotensin converting enzyme inhibitor 2. Beta-blockers 3. Mineralocorticoid receptor antagonists 4. Devices New Heart Failure Therapies: Large Clinical Trials 1. Sodium glucose cotransporter-2 inhibitors: survival, health status and hospitalization benefit 2. Vericiguat: hospitalization benefit 3. Omecamtiv Mecarbil: heart failure event benefit 4
GALACTIC-HF Discussion Promising Signals for Omecamtiv Mecarbil No reduction in blood pressure Unlike many established therapies. Patient subgroups may be identified with greater benefit Low left ventricular ejection fraction Sinus rhythm 5
